

Consensus Controversy?

Clinical Investigators Provide Their Perspectives on Practical Issues and Research Questions in the Management of Breast Cancer

Select Publications

Baselga J et al. **First results of the NeoALTTO trial (BIG 01-06/EGF 106903): A Phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer.** San Antonio Breast Cancer Symposium 2010;Abstract S3-3.

Bear HD et al. **The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40.** *Proc ASCO* 2011;Abstract LBA1005.

Burris HA 3rd et al. **Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.** *J Clin Oncol* 2011;29(4):398-405.

Cancello G et al. **Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes.** *Breast Cancer Res Treat* 2011;127:713-20.

Coleman RE et al. **Adjuvant treatment with zoledronic acid in Stage II/III breast cancer. The AZURE trial (BIG 01/04).** San Antonio Breast Cancer Symposium 2010;Abstract S4-5.

Cortes J et al. **Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study.** *Lancet* 2011;377(9769):914-23.

Ellis PA et al. **Ongoing clinical development of lapatinib in HER2-positive (HER2+) metastatic breast cancer (MBC): An innovative approach to recruit patients in clinical studies.** *Proc ASCO* 2011;Abstract TPS105.

Gerber B et al. **Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 686 triple-negative primary breast cancers: Secondary endpoint analysis of the GeparQuinto study (GBG 44).** *Proc ASCO* 2011;Abstract 1006.

Gianni L et al. **Neoadjuvant pertuzumab (P) and trastuzumab (H): Antitumor and safety analysis of a randomized Phase II study ('NeoSphere').** San Antonio Breast Cancer Symposium 2010;Abstract S3-2.

Giuliano AE et al. **Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: A randomized clinical trial.** *JAMA* 2011;305:569-75.

Giuliano AE et al. **ACOSOG Z0011: A randomized trial of axillary node dissection in women with clinical T1-2 N0 M0 breast cancer who have a positive sentinel node.** *Proc ASCO* 2010;Abstract CRA506.

Gnant M et al. **Overall survival with adjuvant zoledronic acid in patients with premenopausal breast cancer with complete endocrine blockade: Long-term results from ABCSG-12.** *Proc ASCO* 2011;Abstract 520.

Gonzalez-Angulo AM et al. **SWOG S1007: A phase III, randomized clinical trial of standard adjuvant endocrine therapy with or without chemotherapy in patients with one to three positive nodes, hormone receptor (HR)-positive, and HER2-negative breast cancer with recurrence score (RS) of 25 or less.** *Proc ASCO* 2011;Abstract TPS104.

Loibl S et al. **313 patients with breast cancer during pregnancy — Results from a prospective and retrospective registry (GBG-20/BIG02-03).** San Antonio Breast Cancer Symposium 2010;Abstract S6-2.

O'Shaughnessy J et al. **A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC).** *Proc ASCO* 2011;Abstract 1007.

Patterns of Care: Breast Cancer Edition, Issue 1, 2011. Available at: <http://www.researchtopractice.com/POCB111>.

Twelves C et al. **The relationship between age and survival outcomes for eribulin in metastatic breast cancer.** *Proc ASCO* 2011;Abstract 1060.

Untch M et al. **Lapatinib vs trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy: Primary efficacy endpoint analysis of the GEPARQUINTO STUDY (GBG 44).** San Antonio Breast Cancer Symposium 2010;Abstract S3-1.

Verma S et al. **EMILIA: A phase III, randomized, multicenter study of trastuzumab-DM1 (T-DM1) compared with lapatinib (L) plus capecitabine (X) in patients with HER2-positive locally advanced or metastatic breast cancer (MBC) and previously treated with a trastuzumab-based regimen.** *Proc ASCO* 2011;Abstract TPS116.

Von Minckwitz G et al. **Neoadjuvant chemotherapy with or without bevacizumab: Primary efficacy endpoint analysis of the GEPARQUINTO Study (GBG 44).** San Antonio Breast Cancer Symposium 2011;Abstract S4-6.

Von Minckwitz G et al. **Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A German Breast Group 26/Breast International Group 03-05 study.** *J Clin Oncol* 2009;27(12):1999-2006.

ALTTO: A randomised, multi-centre, open-label, Phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer. **NCT00490139.**

A Phase II trial of adjuvant paclitaxel and trastuzumab for node-negative HER2-positive breast cancer. **NCT00542451.**

BETH: A multicenter Phase III randomized trial of adjuvant therapy for patients with HER2-positive node-positive or high risk node-negative breast cancer comparing chemotherapy plus trastuzumab with chemotherapy plus trastuzumab plus bevacizumab. **NCT00625898.**

NSABP-B-34: A clinical trial comparing adjuvant clodronate therapy vs placebo in early-stage breast cancer patients receiving systemic chemotherapy and/or hormonal therapy or no therapy. **NCT00009945.**

SWOG-S0307: Phase III trial of bisphosphonates as adjuvant therapy for primary breast cancer. **NCT00127205.**